Daily non-political popular news in brief.

Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with esophageal cancer, according to a study published last month in the Annals of Surgery. The authors say their finding is particularly important because the focus of recent pathological studies of response to neoadjuvant therapies has been on the primary tumor rather than nodal sites.

Read more »

Keywords: nodal, status, predictor, outcome, neoadjuvant, therapy, esophageal, cancer, statu

« Previous | Next »

Similar news on "Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer":

1. Obesity linked to acid reflux disease
   12-12-2006 · EurekAlert!
   According to a new article in the American Journal of Gastroenterology, gastroesophageal reflux disease (GRD), more commonly known as, acid reflux, is linked to obesity. Since (GRD) is strongly associated with more serious conditions, such as esophageal ulcers and cancer, weight reduction therapy may be useful in treatment and prevention of these conditions.
   Similar news · Read more »
   
2. Women with breast cancer do not get potentially life-saving information, survey reveals
   05-24-2007 · EurekAlert!
   New published data from a large pan-European survey indicate that the majority of postmenopausal women with early breast cancer taking post-surgical endocrine therapy are not involved in making key decisions about their treatment, nor are they given sufficient information to make informed treatment choices that could affect their long-term outcome.
   Similar news · Read more »
   
3. Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
   01-02-2008 · EurekAlert!
   Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years -- especially the development of bone metastases -- and increased survival in older men with potentially aggressive prostate cancer. This "neoadjuvant" hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on.
   Similar news · Read more »
   
4. Aspirin reduces esophageal-cancer risk in people with most-aggressive form of Barrett's esophagus
   02-26-2007 · EurekAlert!
   People with the most-aggressive form of Barrett's esophagus, a precancerous condition that can lead to esophageal cancer, may benefit the most from preventive therapy with aspirin and other NSAIDs.
   Similar news · Read more »
   
5. Gene patenting -- steep cost for health care and patients
   05-07-2007 · EurekAlert!
   The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
   Similar news · Read more »
   
6. High pretreatment PSA velocity predicts worse outcome
   05-25-2007 · EurekAlert!
   The most significant single predictor of aggressive prostate cancer is an elevated rate of increase in prostate specific antigen (PSA) levels, according to a new study.
   Similar news · Read more »
   
7. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
   09-25-2007 · EurekAlert!
   Researchers have found that the breast cancer susceptibility gene, BRCA1, plays a significant role in nonsmall cell lung cancer. They told the European Cancer Conference in Barcelona that not only can it be used to predict outcome for patients with NSCLC, but it may also prove to be a valuable tool in choosing the best therapy for them.
   Similar news · Read more »
   
8. Antiprotons 4 times more effective than protons for cell irradiation
   10-31-2006 · EurekAlert!
   A pioneering experiment at CERN with potential future application in cancer therapy has produced its first results. Started in 2003, ACE (Antiproton Cell Experiment) is the first investigation of the biological effects of antiprotons.
   Similar news · Read more »
   
9. Growth factor signals influence balance between normal growth and cancerous growth
   11-09-2006 · EurekAlert!
   Too much of a signaling protein called insulin-like growth factor-I (IGF-I) may fan the flames of cancer, while too little of the protein may cause short stature, dementia and osteoporosis. New research investigates how the growth hormone/IGF system is affected by the important tumor suppressor gene p53. This interplay of two signaling pathways reinforces questions about the long-term risks of prescribing growth hormone, while suggesting a future new avenue for cancer therapy.
   Similar news · Read more »
   
10. Chemo combo fights cancer
    11-23-2006 · EurekAlert!
    Bacteria that can cause deadly infections in humans and animals have shown promise in treating cancer by "eating" tumors from the inside out. Now, two new studies at the Johns Hopkins Kimmel Cancer Center have demonstrated that, combined with specially-packaged anti-cancer drugs, the bacterial therapy's prospects for cancer eradication have dramatically improved.
    Similar news · Read more »